<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this study is to prospectively evaluate the efficacy of combination chemotherapy with every second week cetuximab and irinotecan in patients with pretreated <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> harboring <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> that had progressed after chemotherapy with irinotecan, <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>, and fluoropyrimidine were included </plain></SENT>
<SENT sid="2" pm="."><plain>Cetuximab was administered at 500 mg/m(2) biweekly with irinotecan </plain></SENT>
<SENT sid="3" pm="."><plain>The primary endpoint was response rate </plain></SENT>
<SENT sid="4" pm="."><plain>The pharmacokinetics of cetuximab was also evaluated in 5 patients </plain></SENT>
<SENT sid="5" pm="."><plain>From May 2009 to February 2010, a total of 31 patients were enrolled from five institutions </plain></SENT>
<SENT sid="6" pm="."><plain>One patient was not eligible </plain></SENT>
<SENT sid="7" pm="."><plain>Among the 30 patients who were treated with biweekly cetuximab plus irinotecan, partial response was observed in 9 patients </plain></SENT>
<SENT sid="8" pm="."><plain>The objective response rate was 30.0% (95% confidence interval [CI], 14.7%-49.4%) and the disease control rate (complete response, partial response, or stable disease) was 76.7% (95% CI, 57.7%-90.0%) </plain></SENT>
<SENT sid="9" pm="."><plain>The median progression-free survival was 5.3 months and median overall survival was 10.8 months </plain></SENT>
<SENT sid="10" pm="."><plain>Grade 3 skin toxicity was observed in 3 patients (10.0%) and one treatment related <z:hpo ids='HP_0011420'>death</z:hpo> due to <z:hpo ids='HP_0002090'>pneumonia</z:hpo> was observed </plain></SENT>
<SENT sid="11" pm="."><plain>Combination chemotherapy with biweekly cetuximab and irinotecan was effective for pretreated <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> with <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS </plain></SENT>
</text></document>